devote like today's in innovation discussion management a non-opioid remarks Susan. pain business before most time cover to across prepared continues Good entire highlights our with notable place recent everyone. drive to to of you, today. XXXX. and to first taking quarter our we'd you morning, of where begin of your for questions, turning with Pacira thank progress few the Thank We'll And portfolio joining us.
March. $XX Passover the and across continue are settings for in record coupled objectives surgical high COVID-related operational as exceeded sites first positive Easter quarter all the and sales to the over our in surgery our EXPAREL of elective continue sequentially top operational continues adjusted and labor cap quarter, demonstrated outpatient over with market and recent marking We along sales to a efficiency impressive market, of of especially when by quarter expand outperforming which that well month the with April. consecutive line to around drive XXth shortages, with our pockets first margin off care. first This period, Strong levels. EXPAREL attractive adjusted margins the given to particularly of is to persisting elective pleased XX% very period utilization the This healthy of the data, transition ongoing is significantly which million EXPAREL pre-COVID consistently and baseline disruptions in available EBITDA. quarter support shows for surgery as latest EBITDA the weekly within the market compared holidays
block IQVIA Our regional the website. developing is and EXPAREL of recent it data revolution new that are most Relations anesthesia a field existing number protecting section so Anesthesiologists in in this nerve Investor are available one are based fueling blocks techniques. not driver. our growth is blocks our segment surprising blocks while
remain ensure with who eager surgery shortly blocks patients iovera° times aim meetings A engage enabling education control In element as are blocks for regional anesthesiologists best to well training after utilize important in and practice us In-person surgery. expedite pain and cases directly with clinicians around to successful injections society for to and recovery is to pain. for the drug-free outcomes. imaging osteoarthritic approaches addition, and nerve with ZILRETTA ambulatory ensure knee intra-articular critically as patient and EXPAREL back discharge as
training and – teams PITT, for coverage. and requested, we most alone, first Tampa real-time XX on with block knowledge to training safety simplicity, migration practice its broad given the best center accelerate had in-bound and state-of-the-art their underscoring institutions leveraging We for requests the spinae quarter transfer popularity sites or innovation outpatient our are being anesthesia requesting opportunity In ESP select care. erector to its in of blocks growing surgical facilitate
to workshops continues host also and remain team monthly innovation where and high. interest attendance medical Our
opening will this have Houston, year. later look forward development training We plans in launched our for facility innovation we and to second which
broadcast This driving EXPAREL impact cutting-edge the positive facility procedures, for especially studio, on core to field our our feature These are developing and labs training clinicians, state-of-the-art block equally opioid-sparing of physician an interactive both and have will iovera° workshops. cadaver the imaging forefront management. are dedicated centers want and for adaptive growth. clinicians lecture nerve among to hall, Houston expect stay who other pain will space on which champions We expanding and advanced majority an and expertise community-based of
utilization recent standard of this EXPAREL EXPAREL a procedures based safely to few XX% have care. IQVIA continue EXPAREL orthopedic to a XXXX. and of well five January listed period with shift we regional performing quickly are strategy protocols segment. of year-over-year October extend around enabling EXPAREL pediatrics, XXXX procedures growing our advance data robust same the in in patent utilization most care. is for patents up Importantly, markets, our showing now sites with which from protection expect our orthopedic the to market six orthopedic have a down and Drilling in XX-hour EXPAREL new and weeks. intellectual FDA's and property Orange pumps issue coming XX% are up significantly key In over patents catheters replacing and the XX, very as reliably with Book the EXPAREL fortified patents, We into
drive latest are techniques. medical education around continuing the to We
seeing from with exchange, In oncology procedures. Tampa pediatric will clinical in pediatric launching institutions halo women's augmentation These patients share pain market and center, these surgeons, see C-section trauma opioid-sparing and experience early new expanded from production pediatric a we significant cardiovascular injury-related and in growth success and vulnerable the pediatric deformity, we utilization continue feature and nationally regional In addition spine are monthly pediatric to nurses where who which in and and breast and gynecologic remain [indiscernible]. management procedures. innovation their a recognized Later will EXPAREL. outcomes to and is month, health, with driving our are surgeries, powerful emerging we are the anesthesiologists effect this blocks days experiencing training
high evidenced to where recent are and Society of of interest was regional the educational same surgeries engagement Gynecologic lift focused at on at Society the including the growing a American Surgeons, setting. and we XX-hour Breast blocks – Surgeons. our Gynecologic Oncology neuroanatomy, seeing events also by of seeing day level of also are congresses, The health EXPAREL of techniques Society level and We a regional around women's the recently
our European to team waitlist progress. as strong launch, but place. been in EXPAREL one full to work in by through years. of now steady interest Regarding We've in Europe slow continue surgical the with physicians make a have encouraged we backlog a two And
techniques virtual surgeons multimodal and We are using and after our to therapy EXPAREL pain center iovera° train and utilizing anesthesiologists surgery enhanced our effectively best capabilities Tampa innovation from and management practice recovery European protocols.
And as Planning quarter. a ganglion studies supplemental registry will from cardiac in also is lower year. X Shivkumar will to which lasts be block include of for renowned Dr. and to is study and at team with by the NDA care. finalized block, design investigator Dr. and Looking multimodal the tend our the support study leading collaborating the successful evaluating stellate EXPAREL this several dysrhythmia. studies of registration extremity is align in design world end the refractories way with the with treating Stellate Shivkumar, be will multicenter mechanisms are blocks refractory block. once principle on the in If filing arrhythmias patient EXPAREL Center regulatory these for meet on FDA a of expert third study the with a the Phase advancing two days a nerve data pipeline, of expected strategy EXPAREL significant stellate underway Director and forward. UCLA improvement ganglion cardiac Arrhythmia and expanding for to for Cardiac EXPAREL label
performed strong support of rationale the while of the well, with our Flexion perform Beyond continues for our stage acquisition our Out combination. growth and to EXPAREL, gate, franchise its success in has of trajectory. early still the ZILRETTA this
We product the are We align, needs To recently of acquisition our will volume-based a discounting an earnings be distribution ZILRETTA program. contributor. with confident and revenue introduced this simplified better tiered and important customers.
customers We outlays patterns expect treatment embedding earlier normalize cash the in our ordering paradigm. and ZILRETTA while this will for
the with coming new currently that discuss market in to a indication and to quarter. in Beyond including third FDA opportunities indications study the expansion Phase and intend X advance years, we to for a pipeline ZILRETTA, we the continue product and shoulder drive growth label the of
safety We are the diabetic ZILRETTA to regulatory to data dosing Type defining a add and repeat label. and patients also X pathway
implementing we to initial phase novel software Generation a our the further based on market to update device. slower Generation transitioning working X users. rollout iovera° toward are to experience new as during been received the handheld X than we device, to of our iovera°, to has optimize our Moving are launch top broad user The a cryotherapy of anticipated the base feedback customer the
following Turning of close study to iovera° interim study we an the and early. to PREPARE TKA the decided review,
rapidly target reflects the towards providers the delivered to use our support commercial medicine management was around knee. no and market osteoarthritis nerves is guided tip The it moving ultrasound non-operative specialists practice to likely blocks of sports reimbursement These a XXX design iovera° the current patterns. longer market's longer by As under ultrasound since precisely associated deeper with with This pain anesthesiologists, clinicians. visualization IGOR our data is in IGOR centers and paradigm confirms iovera°, which now approach positioned reflecting of with with newer iovera° study accuracy The evolving knee – as real ZILRETTA real-world location registry leading of excellence. centers treatment. support in provide ensures of care evidence better the nerve both is to by these capturing and osteoarthritic commercial standards time. will leading treatment initiatives goals
for and arthroplasty the block, we for in iovera° as use novel cold particularly to addition peripheral a opportunity treating In approach remain excited knee therapy nerve spasticity. to total
is to President we on a encouraging, As the strategy continues findings conducting In our teams for iovera° Winston’s Medicine Dr. of and and Association we working with study of publication has The studies you Rehabilitation evaluate Winston, may he to spasticity. of parallel, preliminary designing of and with who data. are in been Paul clinical these collaborating be been Physical now treatment registration Canadian iovera° observational spasticity. have highly a medical recall, and the Dr. research
year meet limited We FDA design. have the expect secure with later study and on alignment this costly to currently options. therapeutic often Patients to
at treatment. $X,XXX treatments patients example, are $X,XXX receiving per year four For to to BOTOX three a
a of a and cerebral has are is promise could shown policy outcomes proposition in spasticity. adjacent an cerebral treatment – is EXPAREL treatment in our great spasticity. treat as An stellate with with In initiating that to this off-label $XXX to also technology indication long-term approach patients utilizing tremendous – a tissue the a the of Shiv would example ganglion cryo pediatric use requires iovera° ganglion Another iovera°’s iovera° to the stellate study value efficacy significant a variable. neurolytic. effectively, has Dr. a block Phenol and parallel pediatric in to to iovera° is patients address and study patients. phenol $XXX, Kumar infarction. In effective advance disease myocardial iovera° potential highly both stroke effectively post post various wide that occur and of and chemical be anesthesia sorry those such range scarring and to EXPAREL for as the address contrast, persistent Smart I’m represent acute painful, Tips safe cardiac arrhythmias in have cardiac costing
to opportunities now to earlier make Moving our where we pipeline continue stage progress.
year. X this expect We initiate subarachnoid in to EXPAREL later Phase study a analgesia of
programs formulations days we for In and longer for low for pain bupivacaine dose are dexamethasone multivesicular of five addition, proprietary high acting inflammation defining of clinical or liposomes more. and our back management pain
CX-XXX remain of to Lastly, by in development closing, injection ILX of front we position about the designed the mediating recently we to started today. where investment of made degeneration continue development we joint active slow stand In in support a and great the we and to final CarthroniX in and feel a stages strength XXXX cytokines. strategic business preclinical interarticular
our team, to quarter right And shareholder first highlights. patients need solutions and to growth. the earnings we that, the leadership and remain Charlie pathway, have confident cement the and our bearing value. along Charlie? the highly his call in right neuro With outlook we a in to and delivering opioids the than we’re across strategy wind building that options We ever are patient have and strong for for and innovative sign I’ll over for non-opioid franchises with multiple relationship, limited right our our competition, commercial significant non-opioid products significant a revenue sales financial turn position now confident more
